Gene therapy formulations are a special class of biological products, they usually contain living organisms with nucleic acids and proteins, and are therefore very sensitive to changes in environmental conditions, especially to factors such as heat, ultraviolet light, freezing and thawing. Stability testing of gene therapy formulations can provide a scientific basis for the production process, packaging, storage conditions and the establishment of analytical methods for degradation products by studying the intrinsic stability of the drug, understanding the factors affecting its stability and the possible degradation pathways and degradation products.
CD Formulation provides advanced and reliable technical support and comprehensive analytical solutions for gene therapy formulation stability testing. Our professional technical team has rich experience in gene therapy formulation stability studies, and working with us can greatly help you advance your gene therapy formulation development process.
Because stability testing directly affects the resulting medicine's safety and effectiveness and is a crucial component of drug development, it is essential for gene therapy formulations. Stability testing can serve as a foundation for developing standards for product quality as well as for the manufacturing procedure, formulation prescription, packaging materials, storage, and transportation conditions of gene therapy formulations.
We offer stability testing for gene therapy formulations to help developers better optimize formulations, select appropriate excipients, and determine suitable storage conditions to maximize control over the stability and safety of gene therapy formulations.
Gene therapy formulations are a special class of biological products, they usually contain living organisms with nucleic acids and proteins, and are therefore very sensitive to changes in environmental conditions, especially to factors such as heat, ultraviolet light, freezing, and thawing. Stability testing of gene therapy formulations can provide a scientific basis for the production process, packaging, storage conditions, and the establishment of analytical methods for degradation products by studying the intrinsic stability of the drug, and understanding the factors affecting its stability, as well as the possible degradation pathways and degradation products.
The stability study of gene therapy products includes long-term stability study, accelerated stability study and forced condition test study. Long-term stability study is carried out under the actual storage conditions to provide the main basis for setting the preservation conditions and expiration date of the product. Accelerated stability studies are conducted under conditions higher than the actual storage temperature, while forced condition test studies are stability studies conducted under extreme conditions, such as high temperature, light, vibration, repeated freezing and thawing, oxidation, and so on. Our stability studies of gene therapy formulations need to take into account a variety of factors, including storage duration, transportation conditions, and so on.
We follow the development direction of gene therapy technology and continuously optimize our methods and standards for stability testing, and can focus on personalized and precise stability testing solutions to suit the characteristics of different gene therapy preparations according to the conditions and requirements of our customers' projects. In addition, based on our in-depth understanding of the factors affecting the stability of gene therapy formulations, we aim to provide researchers with better protective agents and storage conditions for the development of gene therapy formulations, to improve the stability and safety of the products.
Our Projects | Content Description |
---|---|
Activity | Activity is a key research program in stability studies, and activity determinations usually include determinations of the efficiency of gene transfer (infectivity, transduction efficiency, delivery efficiency), the level of expression of the therapeutic sequence, the function of the expression product, or the direct activity of the whole product. We generally define quantitative methods to help our customers determine the activity of gene therapy formulations. |
Purity and impurities | The total purity level of the product may be assessed by HPLC, SDS-PAGE, UV absorption, and other methods. Impurities include product-related impurities and process-related impurities, in which the level of product-related impurities better reflects the stability of the product, and we can help customers effectively analyze carrier degradation and aggregation. |
Content | Total particle number, infectious titer or infectious particle number, genomic DNA or RNA should be analyzed, and the ratio of physical quantities, such as total particle number or genomic copy number, to infectious titer should also be determined. |
Particle characterization | The particle characteristics of viral vector-based gene therapy formulations are susceptible to changes in storage time, temperature, repeated freezing and thawing, and other factors, and are an important indicator of the stability of gene therapy formulations. Our assays include visible foreign matter, insoluble particles, particle size and size distribution, refractive index, and aggregate analysis. |
Journal: J Pharm Sci
IF: 3.8
Published: 2004
In this article, the authors evaluated the stability characteristics of adenovirus vaccine formulations to identify liquid formulations that are stable during long-term storage at 4 degrees Celsius. By identifying the major physicochemical inactivation pathways during storage, Ad5 formulations were designed with specific pharmaceutical excipients that greatly enhance stability. For example, the results indicate that nonionic surfactants and cryoprotectants, as well as excipients known to inhibit free radical oxidation, stabilize Ad5. The nonionic surfactants are necessary to prevent adenovirus adsorption to glass surfaces during storage, and the cryoprotectants are necessary to prevent freeze-thaw-induced virus inactivation.
CD Formulation is an industry leader in stability testing of gene therapy formulations, and we have established a comprehensive stability testing platform to support our customers in the development of gene therapy formulations for a wide range of stability testing studies. If you are interested in us, please feel free to contact us.
References